ArticleBMC research notes2025
Predictive model for carbapenem-resistant Klebsiella pneumoniae bloodstream infection based on a nomogram: a retrospective study.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors for carbapenem-resistantFrontiers in public health · 2026Pooled it
- Analysis of risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infections in children: a case-control study.BMC microbiology · 2026Article
- A nomogram for predicting 30-day mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study.BMC infectious diseases · 2026Article
- Machine learning-assisted prognostic model for mortality in ICU patients with culture-confirmedFrontiers in cellular and infection microbiology · 2026Article
- Research article proteomics-based plasma biomarkers for predicting CRKP infection in ICU sepsis patients.Frontiers in pharmacology · 2026Article
- Risk factors for quinolone-resistantFrontiers in pediatrics · 2026Article
- FromFrontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveCarbapenem-resistant Klebsiella pneumoniae bloodstream infections (BSIs-CRKP) are associated with high mortality rates, necessitating early risk stratification tools. This study aimed to identify risk factors and develop a nomogram model to predict BSIs-CRKP in hospitalized patients. A single-center retrospective case-control study was conducted at Shaanxi Provincial People's Hospital (2017-2024). Patients with Klebsiella pneumoniae bacteremia were stratified into CRKP (n = 154) and carbapenem-susceptible (CSKP, n = 233) groups. Clinical data, including demographics, comorbidities, treatments, and antimicrobial exposure, were analyzed. Risk factors were identified via multivariate logistic regression, and a nomogram model was developed using R software. Model performance was evaluated using ROC curves, calibration plots, and the Hosmer-Lemeshow test.
resultsIndependent risk factors for BSIs-CRKP included indwelling urinary catheterization (OR = 2.531, P = 0.038), central venous catheterization (OR = 2.673, P = 0.015), immunosuppressant use (OR = 3.782, P = 0.006), carbapenem exposure (OR = 4.470, P < 0.001), and age ≥ 65 years (OR = 3.740, P = 0.002). A nomogram model was constructed based on these risk factors, which demonstrated good predictive performance with an area under the curve (AUC) of 0.878 (95% CI: 0.845-0.910) and exhibited excellent calibration (Hosmer-Lemeshow, P = 0.234). This nomogram model effectively stratifies BSIs-CRKP risk using five clinically accessible variables. External validation and integration of genomic data are warranted to enhance generalizability and precision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.